Jan Davidson

Company: Macrogenics

Job title: Director of Clinical Development & Research

Seminars:

Flotetuzumab: An Experimental CD123 x CD3 Bispecific DART Molecule for the Treatment of AML 4:05 pm

Clinical study design: Dose and schedule optimization to mitigate cytokine release and deliver target dose Pharmacokinetics & pharmacodynamic: Correlation with designed mechanism of action Biomarker analysis: Identification of primary refractory and early relapse patients as a responsive populationRead more

day: Day One